ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Tao Zhang
Matched on ORCID iD 0000-0001-8482-1954; OpenAlex author ID A5100375859. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2022: 1 paper · 2023: none · 2024: 1 paper
Papers 2
- Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study. Last author DOI 10.1093/oncolo/oyae171↗
- Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jun Xue · 1 shared paper, 2024 · strength 0.19
- Min Jin · 1 shared paper, 2024 · strength 0.19
- Zhenyu Lin · 1 shared paper, 2024 · strength 0.19
- Hongli Liu · 1 shared paper, 2024 · strength 0.19
- Jianli Hu · 1 shared paper, 2024 · strength 0.19
- Feng Jiao · 1 shared paper, 2022 · strength 0.09
- Zheng Wang · 1 shared paper, 2022 · strength 0.09
- Zhiwei Li · 1 shared paper, 2022 · strength 0.09
- Qingyong Ma · 1 shared paper, 2022 · strength 0.09
- Liwei Wang · 1 shared paper, 2022 · strength 0.09
- Chunyi Hao · 1 shared paper, 2022 · strength 0.09
- Gang Ren · 1 shared paper, 2022 · strength 0.09
- Jie Chen · 1 shared paper, 2022 · strength 0.09
- Dan Cao · 1 shared paper, 2022 · strength 0.09
- Jian Wang · 1 shared paper, 2022 · strength 0.09
- Yongrui Bai · 1 shared paper, 2022 · strength 0.09
- Zhihong Zhang · 1 shared paper, 2022 · strength 0.09
- Yongwei Sun · 1 shared paper, 2022 · strength 0.09
- Ji Li · 1 shared paper, 2022 · strength 0.09
- Jianping Xiong · 1 shared paper, 2022 · strength 0.09
- Jun Zhou · 1 shared paper, 2022 · strength 0.09
- Feng‐Hua Wang · 1 shared paper, 2022 · strength 0.09
- Leizhen Zheng · 1 shared paper, 2022 · strength 0.09
- Da Li · 1 shared paper, 2022 · strength 0.09
- Chengfeng Wang · 1 shared paper, 2022 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.